87 related articles for article (PubMed ID: 20177382)
21. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma.
Hammock L; Cohen C; Carlson G; Murray D; Ross JS; Sheehan C; Nazir TM; Carlson JA
J Cutan Pathol; 2006 Sep; 33(9):599-607. PubMed ID: 16965333
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
23. [Involvement of matrix metalloproteinases (MMPs) in cutaneous melanoma progression].
Ntayi C; Hornebeck W; Bernard P
Pathol Biol (Paris); 2004 Apr; 52(3):154-9. PubMed ID: 15063935
[TBL] [Abstract][Full Text] [Related]
24. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
Francken AB; Shaw HM; Thompson JF; Soong SJ; Accortt NA; Azzola MF; Scolyer RA; Milton GW; McCarthy WH; Colman MH; McGovern VJ
Ann Surg Oncol; 2004 Apr; 11(4):426-33. PubMed ID: 15070604
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of extent of ulceration in primary cutaneous melanoma.
Grande Sarpa H; Reinke K; Shaikh L; Leong SP; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2006 Nov; 30(11):1396-400. PubMed ID: 17063079
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
28. Molecular staging for patients with malignant melanoma.
Shivers S; Jakub J; Pendas S; Reintgen D
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1665-74. PubMed ID: 18020932
[TBL] [Abstract][Full Text] [Related]
29. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.
Gimotty PA; Guerry D; Ming ME; Elenitsas R; Xu X; Czerniecki B; Spitz F; Schuchter L; Elder D
J Clin Oncol; 2004 Sep; 22(18):3668-76. PubMed ID: 15302909
[TBL] [Abstract][Full Text] [Related]
30. Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Nambiar S; Mirmohammadsadegh A; Doroudi R; Gustrau A; Marini A; Roeder G; Ruzicka T; Hengge UR
Arch Dermatol; 2005 Feb; 141(2):165-73. PubMed ID: 15724012
[TBL] [Abstract][Full Text] [Related]
31. Update of diagnostic and prognostic markers in cutaneous malignant melanoma.
Reed JA; Albino AP
Clin Lab Med; 2000 Dec; 20(4):817-38. PubMed ID: 11221516
[TBL] [Abstract][Full Text] [Related]
32. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma.
Barnhill RL; Katzen J; Spatz A; Fine J; Berwick M
J Cutan Pathol; 2005 Apr; 32(4):268-73. PubMed ID: 15769275
[TBL] [Abstract][Full Text] [Related]
33. Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma.
Vollmer RT; Seigler HF
Am J Clin Pathol; 2001 Feb; 115(2):205-12. PubMed ID: 11211608
[TBL] [Abstract][Full Text] [Related]
34. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
35. Pathology of melanocytic lesions: new, controversial, and clinically important issues.
Scolyer RA; Thompson JF; Stretch JR; Sharma R; McCarthy SW
J Surg Oncol; 2004 Jul; 86(4):200-11. PubMed ID: 15221927
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T
Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184
[TBL] [Abstract][Full Text] [Related]
37. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of CCN3 expression as a potential mechanism for melanoma progression.
Fukunaga-Kalabis M; Martinez G; Telson SM; Liu ZJ; Balint K; Juhasz I; Elder DE; Perbal B; Herlyn M
Oncogene; 2008 Apr; 27(18):2552-60. PubMed ID: 17968313
[TBL] [Abstract][Full Text] [Related]
39. [Histopathological diagnosis of primary melanoma in 2011 and beyond?].
Vernez M; Hohl D
Rev Med Suisse; 2011 Apr; 7(289):739-40, 742-4, 746. PubMed ID: 21568095
[TBL] [Abstract][Full Text] [Related]
40. Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype.
Barricklow Z; DiVincenzo MJ; Angell CD; Carson WE
Clin Cosmet Investig Dermatol; 2022; 15():1743-1757. PubMed ID: 36065342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]